Global, regional, and national causes of under-5 mortality in 2000-19: an updated systematic analysis with implications for the Sustainable Development Goals.


Journal

The Lancet. Child & adolescent health
ISSN: 2352-4650
Titre abrégé: Lancet Child Adolesc Health
Pays: England
ID NLM: 101712925

Informations de publication

Date de publication:
02 2022
Historique:
received: 29 06 2021
revised: 29 09 2021
accepted: 30 09 2021
pubmed: 21 11 2021
medline: 19 2 2022
entrez: 20 11 2021
Statut: ppublish

Résumé

Causes of mortality are a crucial input for health systems for identifying appropriate interventions for child survival. We present an updated series of cause-specific mortality for neonates and children younger than 5 years from 2000 to 2019. We updated cause-specific mortality estimates for neonates and children aged 1-59 months, stratified by level (low, moderate, or high) of mortality. We made a substantial change in the statistical methods used for previous estimates, transitioning to a Bayesian framework that includes a structure to account for unreported causes in verbal autopsy studies. We also used systematic covariate selection in the multinomial framework, gave more weight to nationally representative verbal autopsy studies using a random effects model, and included mortality due to tuberculosis. In 2019, there were 5·30 million deaths (95% uncertainty range 4·92-5·68) among children younger than 5 years, primarily due to preterm birth complications (17·7%, 16·1-19·5), lower respiratory infections (13·9%, 12·0-15·1), intrapartum-related events (11·6%, 10·6-12·5), and diarrhoea (9·1%, 7·9-9·9), with 49·2% (47·3-51·9) due to infectious causes. Vaccine-preventable deaths, such as for lower respiratory infections, meningitis, and measles, constituted 21·7% (20·4-25·6) of under-5 deaths, and many other causes, such as diarrhoea, were preventable with low-cost interventions. Under-5 mortality has declined substantially since 2000, primarily because of a decrease in mortality due to lower respiratory infections, diarrhoea, preterm birth complications, intrapartum-related events, malaria, and measles. There is considerable variation in the extent and trends in cause-specific mortality across regions and for different strata of all-cause under-5 mortality. Progress is needed to improve child health and end preventable deaths among children younger than 5 years. Countries should strategize how to reduce mortality among this age group using interventions that are relevant to their specific causes of death. Bill & Melinda Gates Foundation; WHO.

Sections du résumé

BACKGROUND
Causes of mortality are a crucial input for health systems for identifying appropriate interventions for child survival. We present an updated series of cause-specific mortality for neonates and children younger than 5 years from 2000 to 2019.
METHODS
We updated cause-specific mortality estimates for neonates and children aged 1-59 months, stratified by level (low, moderate, or high) of mortality. We made a substantial change in the statistical methods used for previous estimates, transitioning to a Bayesian framework that includes a structure to account for unreported causes in verbal autopsy studies. We also used systematic covariate selection in the multinomial framework, gave more weight to nationally representative verbal autopsy studies using a random effects model, and included mortality due to tuberculosis.
FINDINGS
In 2019, there were 5·30 million deaths (95% uncertainty range 4·92-5·68) among children younger than 5 years, primarily due to preterm birth complications (17·7%, 16·1-19·5), lower respiratory infections (13·9%, 12·0-15·1), intrapartum-related events (11·6%, 10·6-12·5), and diarrhoea (9·1%, 7·9-9·9), with 49·2% (47·3-51·9) due to infectious causes. Vaccine-preventable deaths, such as for lower respiratory infections, meningitis, and measles, constituted 21·7% (20·4-25·6) of under-5 deaths, and many other causes, such as diarrhoea, were preventable with low-cost interventions. Under-5 mortality has declined substantially since 2000, primarily because of a decrease in mortality due to lower respiratory infections, diarrhoea, preterm birth complications, intrapartum-related events, malaria, and measles. There is considerable variation in the extent and trends in cause-specific mortality across regions and for different strata of all-cause under-5 mortality.
INTERPRETATION
Progress is needed to improve child health and end preventable deaths among children younger than 5 years. Countries should strategize how to reduce mortality among this age group using interventions that are relevant to their specific causes of death.
FUNDING
Bill & Melinda Gates Foundation; WHO.

Identifiants

pubmed: 34800370
pii: S2352-4642(21)00311-4
doi: 10.1016/S2352-4642(21)00311-4
pmc: PMC8786667
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106-115

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests We declare no competing interests.

Références

N Engl J Med. 2018 Apr 26;378(17):1583-1592
pubmed: 29694816
Hum Vaccin Immunother. 2019;15(2):283-286
pubmed: 30252609
N Engl J Med. 2019 Jun 06;380(23):2207-2214
pubmed: 31167050
Bull World Health Organ. 2011 Mar 1;89(3):211-20
pubmed: 21379417
Lancet Glob Health. 2018 Dec;6(12):e1297-e1308
pubmed: 30361107
J Glob Health. 2018 Jun;8(1):010408
pubmed: 29564085
Lancet Glob Health. 2017 Feb;5(2):e186-e197
pubmed: 28007477
Lancet. 2020 Oct 17;396(10258):1160-1203
pubmed: 33069325
Health Policy Plan. 2021 Apr 21;36(3):260-272
pubmed: 33515014
N Engl J Med. 2012 Jul 26;367(4):348-61
pubmed: 22830465
Lancet. 2017 Dec 17;388(10063):3027-3035
pubmed: 27839855
BMJ. 2021 Mar 17;372:n533
pubmed: 33731321
Lancet. 2015 Oct 3;386(10001):1386-1394
pubmed: 25971222
MMWR Morb Mortal Wkly Rep. 2020 Jun 12;69(23):699-704
pubmed: 32525856
Lancet Glob Health. 2016 Dec;4(12):e936-e945
pubmed: 27793587
Arch Public Health. 2020 Aug 24;78:77
pubmed: 32850124
PLoS Med. 2016 Aug 9;13(8):e1002116
pubmed: 27504831
Lancet Glob Health. 2020 Oct;8(10):e1273-e1281
pubmed: 32791117
Lancet. 2016 Aug 27;388(10047):891-7
pubmed: 27372398
Lancet. 2018 Aug 18;392(10147):536-538
pubmed: 30152375
PLoS One. 2012;7(3):e33564
pubmed: 22428070

Auteurs

Jamie Perin (J)

Department of International Health, Johns Hopkins University, Baltimore, MD, USA.

Amy Mulick (A)

Epidemiology and Population Health, London School of Tropical Medicine & Hygiene, London, UK.

Diana Yeung (D)

Department of International Health, Johns Hopkins University, Baltimore, MD, USA.

Francisco Villavicencio (F)

Department of International Health, Johns Hopkins University, Baltimore, MD, USA.

Gerard Lopez (G)

Department of Maternal, Newborn, Child and Adolescent Health and Ageing, World Health Organization, Geneva, Switzerland.

Kathleen L Strong (KL)

Department of Maternal, Newborn, Child and Adolescent Health and Ageing, World Health Organization, Geneva, Switzerland.

David Prieto-Merino (D)

Epidemiology and Population Health, London School of Tropical Medicine & Hygiene, London, UK.

Simon Cousens (S)

Epidemiology and Population Health, London School of Tropical Medicine & Hygiene, London, UK.

Robert E Black (RE)

Department of International Health, Johns Hopkins University, Baltimore, MD, USA.

Li Liu (L)

Department of International Health, Johns Hopkins University, Baltimore, MD, USA; Department of Population, Family, and Reproductive Health, Johns Hopkins University, Baltimore, MD, USA. Electronic address: lliu26@jhu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH